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Fungal infections remain a threat due to the lack of
broad-spectrum fungal vaccines and protective
antigens. Recent studies showed that attenuated
Blastomyces dermatitidis confers protection via T cell
recognition of an unknown but conserved antigen.
Using transgenic CD4+ T cells recognizing this anti-
gen, we identify an amino acid determinant within
the chaperone calnexin that is conserved across
diverse fungal ascomycetes. Calnexin, typically an
ER protein, also localizes to the surface of yeast, hy-
phae, and spores. T cell epitope mapping unveiled a
13-residue sequence conserved across Ascomycota.
Infection with divergent ascomycetes, including
dimorphic fungi, opportunistic molds, and the agent
causing white nose syndrome in bats, induces expan-
sionofcalnexin-specificCD4+Tcells.Vaccinedelivery
of calnexin in glucan particles induces fungal antigen-
specific CD4+ T cell expansion and resistance to
lethal challengewithmultiple fungal pathogens. Thus,
the immunogenicity and conservation of calnexin
make this fungal protein a promising vaccine target.
INTRODUCTION
Major killers such as poliomyelitis have been eradicated, but new
pathogens are emerging. Fungi are one such group, which is
linked partly to modern medical practices. Fungi, from yeasts
colonizing the skin or mucosa to molds from soil or water, are
often harmless in the context of normal host responses. How-
ever, the success of cancer chemotherapy, as well as the AIDS
pandemic, has led to immune deficiencies in a growing segment
of the human population. Likewise, the routine use of intravenous
catheters in hospitals provides a route of access for microbes
that otherwise might not be able to infect human hosts. Candida452 Cell Host & Microbe 17, 452–465, April 8, 2015 ª2015 Elsevier Inis now among the leading agents of nosocomial bloodstream in-
fections (Pfaller et al., 2011). Infection with the mold Aspergillus
is among themost feared complications in patients with hemato-
logical malignancies (Walsh et al., 2008). Over one million new
cases per year of cryptococcosis are estimated worldwide in pa-
tients with AIDS, and over half those affected die of the infection
(Park et al., 2009). Fungal infections have thus become an
important cause of morbidity and mortality and represent an
increasing burden on the medical system. Effective ways to treat
and prevent these infections are badly needed.
Vaccines have been hailed as one of the greatest achieve-
ments in public health during the past century. The global erad-
ication of smallpox virus in humans and rinderpest virus in
animals, and the near eradication or successful prevention of
other viral or bacterial infections—for example, meningitis in chil-
dren due to Hemophilus influenze Type B—offer compelling ex-
amples. Yet, the development of safe and efficacious vaccines
against fungi has been a major hurdle. This difficulty stems
from the relative genetic complexity and intractability of fungi
in the laboratory, limited knowledge of the mechanisms that un-
derpin anti-fungal protective immunity, and a lack of defined
antigen (Ag) candidates for vaccine protection against fungal
pathogens. To date, only two vaccines against fungi havemoved
into clinical trials (Cassone and Casadevall, 2012). An investiga-
tional candidate vaccine containing rAls3p-N (NDV-3), directed
against Candida (and also S. aureus), has been tested for safety
and immunogenicity in volunteers in a Phase I trial. Another
candidate vaccine containing rSap2p was found to be tolerated
and effective in inducing specific antibodies and B cell memory
in women with recurrent vulvovaginitis in a European clinical trial
(Edwards, 2012). Highly conserved Ags that are shared across
fungal pathogens in a family or taxon would be preferable, but
the only such component that has shown promise is b-glucan.
Cassone and colleagues (Torosantucci et al., 2005) reported
that this shared cell wall component served as the basis for a
glyco-conjugate vaccine against Candida and Aspergillus. This
preparation has not yet moved into clinical trials, but b-glucan
particles (GPs) could serve as an experimental platform for the
delivery of candidate vaccines against fungi.c.
We described an effective, live, attenuated vaccine against
infection with Blastomyces dermatitidis (Wu¨thrich et al., 2000).
This dimorphic fungus causes the systemic mycosis blastomy-
cosis and exhibits genetic and morphological similarities to six
related dimorphic fungi that cause human disease: Histoplasma
capsulatum, Coccidioides posadasii and immitis, Penicillium
marneffei, Sporothrix schenckii, and Paracoccidioides brasilien-
sis. The dimorphic fungi are in the fungal taxon Ascomycota,
which includes diverse members such as A. fumigatus and
also the white nose fungus, Pseudogymnoascus destructans,
the cause of epidemic fatal disease spreading among bats
across the U.S. Analysis of the attenuated vaccine against blas-
tomycosis revealed that resistance is mediated by CD4+ T cells;
cloning of the protective T cells disclosed the identity of the T cell
receptor (TCR) and enabled the generation of a TCR (Tg) trans-
genic mouse, termed 1807. TCR Tg 1807 cells recognize and
respond to all the dimorphic fungi of North America (Blastomy-
ces, Histoplasma, Coccidioides) and confer resistance against
lethal experimental infection with each of them (Wu¨thrich et al.,
2011a, 2011b). These findings imply that the T cells recognize
a conserved Ag in dimorphic fungi and perhaps fungal
Ascomycetes.
Here, we sought to identify a conserved Ag in pathogenic
fungi. We used broadly reactive, protective 1807 cells to probe
for such an Ag. We report that calnexin, which is generally
thought of as an intracellular resident of endoplasmic reticulum,
is displayed on the fungal surface and represents the shared Ag
of 1807 cells. We also describe that the calnexin epitope is highly
conserved in the taxon Ascomycota. Finally, by using calnexin-
peptide MHCII tetramers, we show that fungal display of this
sequence across numerous ascomycetes induces the expan-
sion of calnexin-specific CD4+ T cells that can be harnessed
for vaccine immunity against multiple fungal pathogens.RESULTS
Steps Used to Identify Calnexin as the Shared Ag
1807 TCR Tg cells recognize a protective Ag that is shared
among systemic dimorphic fungi (Wu¨thrich et al., 2011b, 2012).
To identify the shared Ag, we prepared a cell wall membrane
(CW/M) extract from B. dermatitidis vaccine yeast (Wu¨thrich
et al., 2000). After running CW/M through a Con A column that
retains mannosylated proteins, we collected Eluate #1, which
contained 1% of the protein present in the starting material (Fig-
ure 1A). Trace Con A released from the column into Eluate #1
was heated to destroy its mitogenic activity (not shown). Eluate
#1 (Figure 1B) was fractioned in a gel-free system to separate
constituents by size (Figure 1C). Fractions 6 and 7 stimulated
1807 T cells to produce IFN-g, whereas medium control and
fractions 5 and 8 did not (Figure 1D). To identify the T cell-reac-
tive Ag, we subjected fraction 7 to mass spectrometry analysis.
Proteins were identified by cross-referencing the mass of de-
tected peptides against a database of the B. dermatitidis prote-
ome. Proteins in non-stimulatory fractions and proteins diverging
from the mass parameters of the gel-free fraction were dis-
counted. This technique yielded a roster of five protein candi-
dates potentially representing the shared Ag. Calnexin was one
of these five proteins (Figure 1E).CellProof that Calnexin Is the Ag
To investigate whether calnexin is the shared Ag that stimulates
1807 T cells, we cloned and expressed fungal calnexin in
E. coli. Twenty-four hours after induction, the crude lysate
from E. coli harbored an additional prominent band that
migrated between 60 and 70 kDa, which corresponds with
the predicted molecular weight (MW) of 63 kD for recombinant
calnexin (r-calnexin) (Figure 1F). We purified r-calnexin over a
Ni-NTA column (Figure 1F) and used the protein to stimulate
1807 cells in an in vitro co-culture system with bone marrow
dendritic cells (BMDCs). 1807 T cells produced IFN-g in
response to r-calnexin in a concentration-dependent manner.
The response to r-calnexin exceeded that to CW/M extract,
which also harbors calnexin at a lower concentration (Fig-
ure 1G). In contrast, r-Drk1, a hybrid histidine kinase of
B. dermatitidis (Nemecek et al., 2006) expressed and purified
from E. coli as a control, did not induce IFN-g production by
1807 T cells. Thus, r-calnexin (not LPS from E. coli) induced
cytokine production by 1807 T cells specifically and in a con-
centration-dependent manner.
To assess whether r-calnexin induces activation and prolifer-
ation of 1807 cells in vivo, we transferred 1807 TCR Tg T cells
into naive wild-type (WT) recipient mice prior to vaccination.
Similar to liveB. dermatitidis vaccine yeast, r-calnexin emulsified
in complete Freund’s adjuvant (CFA) activated and stimulated
proliferation of > 85% of the transferred 1807 cells (Figure 1H),
but adjuvant alone did not. These results identify calnexin as
the shared Ag recognized by 1807 TCR Tg T cells, which confer
immunity to multiple systemic dimorphic fungi (Wu¨thrich et al.,
2011b, 2012).
Evidence that Calnexin Is Displayed on the Surface of
Fungi
Among fungal pathogens, virulence factors and antigenic pro-
teins are largely secreted or associated with the cell wall or sur-
face. Despite the fact that calnexin is a molecular chaperone
and folding sensor that regulates the transport of proteins
from the ER to the Golgi (Ellgaard and Helenius, 2003), vaccina-
tion with B. dermatitidis yeast efficiently stimulates 1807 T cell
responses in vivo. To address this unexpected finding, we
investigated whether calnexin is displayed on the yeast surface.
During our early search for the shared Ag, we found that a wa-
ter-soluble extract of surface proteins from the vaccine strain
yeast activated 1807 T cells (data not shown). Western analysis
of the water-soluble extract detected a doublet that migrated
on SDS-PAGE at the same position as r-calnexin produced
by E. coli (Figure 1I). To investigate whether B. dermatitidis
vaccine yeasts harbor calnexin on their surface, we stained
yeast with polyclonal anti-calnexin antibody. Vaccine yeasts
stained positively with the anti-calnexin serum (Figure 1J).
The virulent parental strain 26199 used for the pulmonary
challenge of mice also harbored calnexin on the yeast surface
(data not shown). Since calnexin is shared among ascomy-
cetes, we tested whether it is also expressed on the surface
of Aspergillus fumigatus. Exposure of hyphae and spores to
anti-calnexin antibody showed punctate surface staining and
fluorescence (Figure 1K). Thus, calnexin is detectable on the
surface of B. dermatitidis yeast and A. fumigatus hyphae and
spores.Host & Microbe 17, 452–465, April 8, 2015 ª2015 Elsevier Inc. 453
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Identification of T Cell Epitopes in Calnexin
We aligned the amino acid (aa) sequence of calnexin from
the fungal species that we have reported to stimulate 1807
T cells in vivo (Wu¨thrich et al., 2011b), including B. dermatitidis,
H. capsulatum, C. posadasii, and P. brasiliensis. We investigated
regionsof sequenceconservation thatmight represent theshared
epitope for the 1807 T cell receptor. We found that calnexin is
highlyconservedacross theentireproteinsequenceamong these
dimorphic fungi (Figure S1). Thus, the identification of highly
conserved areas of the protein was not a sufficient measure to
hone in on the 1807 epitope-containing sequence. To narrow
the focus of possible peptides to test for 1807 reactivity, we
subjected Blastomyces calnexin to two class II I-Ab restricted-
epitope prediction algorithms (Experimental Procedures and Fig-
ure S1). The IEBD algorithm predicted six regions of overlapping
peptide with binding affinity values (IC50) less than 500 nM. In a
second analysis, an algorithm developed by Marc Jenkins (un-
published data) refined the above analysis, predicting ten strong
H2-IAb epitopes in B. dermatitidis calnexin (Figure S1). We syn-
thesized peptides of 13 aa length, representing these ten pre-
dicted epitopes (named peptide #1 through #10) and tested
them to define the cognate epitope for the 1807 T cell receptor.
To test whether the synthetic peptides activate naive 1807
T cells in vitro, we loaded BMDCs with peptides and cultured
them with 1807 cells. Peptide #1 comprised of the sequence
LVVKNPAAHHAIS activated naive 1807 T cells as measured by
their reduced expression of CD62L (Figure 2A) and increased
expression of CD44 (data not shown). An irrelevant control, oval-
bumin (OT-II) peptide, and all other synthetic calnexin peptides
did not activate 1807 cells. Peptide #1 also stimulated the pro-
duction of IFN-g by 1807 cells in a concentration-dependent
manner (Figure 2B). As little as 1–10 nM of peptide #1 stimulated
as much IFN-g as 10 mg/ml of CW/M Ag, which has been shown
to induce substantial amounts of the cytokine (data not shown).
None of the other calnexin peptides induced IFN-g production
by 1807 cells. In vivo, 0.1–1 mg of peptide #1 was enough to
activate and induce the proliferation of naive 1807 T cells (Fig-
ure 2C). Thus, peptide #1 is the T cell epitope recognized by
1807 cells.Calnexin Peptide #1 in Fungi and Activation of T Cells
In Vivo
Weanalyzed conservation of the sequence of peptide #1 broadly
throughout fungi. The 13 aa sequence is found in four phyla,Figure 1. Identity of Shared Fungal Ag
(A) Generation of eluate #1.
(B) Silver-stained PAGE showing examples of crude Ag and eluate #1 of B. derm
(C) Gel-free separation of eluate #1 into fractions.
(D) Stimulation of 1807 TCR Tg cells in vitro by fractions from (C), as measured b
(E) Identification of calnexin by MS/MS. The panel shows data collected for on
comparison of the HPLC separation of the non-stimulatory control fraction (upper
the control. MS of this peak (bottom traces) identified the peptide LQNSLNCG
fraction #7 (lower) versus non-stimulatory control (upper). Adjacent peaks are re
(F) Induction of E. coli produced r-calnexin (63 kDa).
(G) r-Calnexin stimulates 1807 T cells to produce IFN-g in vitro.
(H) r-Calnexin activates (CD44) and induces proliferation (CFSE) of transferred 1
(I) Western blot of crude Ags.
(J and K) Surface stain of B. dermatitidis yeast (strain #55) and A. fumigatus hypha
Cellincluding Ascomycota, Basidiomycota, Chytridiomycota, and
Glomeromycota (Table 1 and Table S1). The highest conserva-
tion of the peptidewas found in ascomycetes. To investigate bio-
logical relevance and test whethermedically important fungi with
conserved peptide #1 sequences trigger the expansion and
activation of TCR Tg 1807 and endogenous, polyclonal, peptide
#1-specific CD4+ T cells in vivo, we transferred naive 1807 T cells
into mice before infection or vaccination with these fungi.
One week later, we analyzed activation of 1807 and also endog-
enous Ag-specific CD4+ T cells using a calnexin peptide-MHC
class II tetramer. B. dermatitidis, A. fumigatus, H. capsulatum,
C. posadasii, Fonsecaea pedrosoi causing chromoblastomyco-
sis (Sousa et al., 2011), and Pseudogymnoascus (Geomyces)
destructans causing white nose syndrome and death in bats in
the U.S. (Lorch et al., 2011) expanded and activated 1807 and
tetramer-positive CD4+ T cells in vivo (Figures 3 and S2, and
data not shown). Fungi that did not trigger expansion of
tetramer-positive CD4+ T cells included Candida albicans, Cryp-
tococcus neoformans, and Pneumocystis jiroveci, none of which
are ascomycetes. Naive mice harbored 29 ± 10 tetramer-posi-
tive CD4+ T cells per animal; hardly any tetramer-positive CD8+
T cells were detected in vaccinated mice (Figure S2A). Thus,
the tetramer recognizes and binds the T cell receptor of calnexin
peptide #1-specific CD4+ T cells in a specific manner and can be
used as a tool tomonitor Ag-specific T cells in vivo in response to
a number of pathogenic fungal ascomycetes.The Basis for Variable Expansion of Peptide-Specific
T Cells by Fungi
We sought to explain the effect of calnexin peptide #1 variation in
fungi. It is likely that the nonamer core for peptide #1 is
VKNPAAHHA (Table 1). For the class II MHC, I-Ab, P1, P3, P4,
P5, P7, and P9 make contacts with I-Ab, and P2, P5, P7, and
P8 are usually the most important TCR contacts, especially P5
(Nelson et al., 2014). Calnexin from C. immitis and Aspergillus
can be detected by VKNPAAHHA:I-Ab-specific T cells because
A or V at P4 are permissive for I-Ab binding and these peptides
have the same TCR contact amino acids at P2, P5, P7, and P8
as calnexin from B. dermatitidis. Conversely, P. carinii may not
be recognized because E at P4 is not permissive for I-Ab binding,
and the peptide likely does not bind I-Ab. Calnexin from
C. albicans is not recognized because R at P4 is not permissive
for I-Ab binding, and thus this peptide likely does not bind I-Ab.
Candida also has a Y for H substitution at P8, which shouldmakeatitidis (space denotes samples are from separate gels).
y IFN-g response. Arrow in fraction 7 denotes material analyzed by MS/MS.
e calnexin-derived peptide as an example. The top set of paired traces is a
) and the stimulatory fraction #7 (lower). The peak in fraction #7 is not present in
GAYMK (728.34 Da; +2H), and this mass is better represented in stimulatory
presentative of isotopic variants.
807 cells in vivo.
e (left) and spores (right) with anti-calnexin oligospecific antibody. Bar = 10 mm.
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Figure 2. Identification of Calnexin’s T Cell Epitope Recognized by 1807 Cells
(A) In vitro activation of 1807 T cells by calnexin peptide #1. 105 BMDCswere loadedwith calnexin (50 mg/ml) or peptide (10 mM) and co-culturedwith 33 105CD4+
purified 1807 T cells. Three days later, T cells were analyzed for activation by flow cytometry.
(B) Naive 1807 T cells were co-cultured as in (A), and culture supernatants were analyzed for IFN-g.
(C) Mice received 106 naive, CFSE-labeled 1807 cells prior to s.c. vaccination with 200 mg r-calnexin, a dilution series of peptide #1 and 250 mg peptide #5 (as a
negative control). Seven days later, the skin draining lymph nodes were harvested, and CFSE profiles and CD44 expression of 1807 cells were analyzed.the peptide unrecognizable to VKNPAAHHA:I-Ab-specific T cells
even if it does bind to I-Ab.
Response to Calnexin in Humans
In a pilot study, we assayed the CD4+ T cell response to calnexin
in human subjects with either a history of confirmed infection due
to dimorphic fungi or residence in an endemic area and labora-
tory evidence of prior infection (immune) versus healthy subjects
that lacked the above features (non-immune) (Figures S3A–S3D).
Five of six immune subjects responded to calnexin versus one of
four non-immune subjects. The response to calnexin in immune
subjects was dose-dependent, similar to that for the immunodo-
minant fungal Ag heat shock protein 60 (Hsp60) and not due to
contaminating LPS.456 Cell Host & Microbe 17, 452–465, April 8, 2015 ª2015 Elsevier InFunctions of Calnexin-Specific T Cell Responses
To test whether vaccination with calnexin induces protective im-
munity against lethal, pulmonary fungal infection, we immunized
mice with r-calnexin. We empirically investigated selected
adjuvants, such as glucan particles (GP), to promote type 17 im-
munity and Adjuplex, type 1 immunity. Vaccination with calnexin
formulated in GP or Adjuplex reduced lung and spleen
colony-forming units (CFU) R 10-fold versus control mice after
infection with B. dermatitidis or C. posadasii (Figures 4A and
4B); reduced lung CFU correlated with prolonged survival (Fig-
ure S4A). Vaccination with calnexin led to increased numbers
of tetramer-positive cells recruited to the lung at day 4 post-
infection (Figure 4C). Of the CD44hi CD4+ T cells recruited to
lung after fungal challenge of Blastomyces yeast-vaccinatedc.
Table 1. The Nine Amino Acid Core Sequence of Calnexin Peptide #1 Is Conserved among Fungal Ascomycetes
Genus/Species/Strain Peptide #1 Core Residue Positions 1807 Reactivea
– – 1 2 3 4 5 6 7 8 9 – – –
Blastomyces dermatitidisb L V V K N P A A H H A I S +
Histoplasma capsulatumc - - - - - - - - - - - - - +
Paracoccidioides brasilliensis Pb18 - - I - - A - - - - - - - ND
Paracoccidioides lutzii Pb01 - - I - - A - - - - - - - +
Coccidioides immitis RS - - - - - A - - - - - - - ND
Coccidioides posadasiid - - - - - A - - - - - - - +
Penicillium marneffei - - L - - - - - - - - - - ND
Penicillium chrysogenum - - - - - A - - - - - - - ND
Aspergillus spp. 1e - - - - - - - - - - - - - ND
Aspergillus spp. 2f - - - - - V - - - - - - - +
Pseudogymnoascus destructans - - - - - A - - - - - - - +
Magnaporthe oryzae 70-15 - - - - - - - - - - - - - ND
Fonsecaea pedrosoig NA NA NA NA NA NA NA NA NA NA NA NA NA +
Cladophialophora carrioniig - - - - - A - - - - - - - ND
Exophiala dermatitidisg - - - - - A - - - - - - - ND
Pneumocystis carinii (rat form 1) - - L - - E - - - - - - - –
Neurospora crassa OR74A - - - - - A - - - - - - - ND
Cryptococcus neoformans - - L - T K - - - - - - - –
Schizophyllum commune H4-8 - - A - T K - - - - - - - ND
Candida albicans 5314 - - M - S R - S - Y - - - –
Homo sapiens (calnexin) - - L M S R - K - - - - - ND
Homo sapiens (calmegin) - - L - S R - K - - - - - ND
-, identical to B. dermatitidis.
aThe data for P. lutzii and C. posadasii were originally reported in Wu¨thrich et al., 2011b. 1807 T cell reactivity was not determined (ND).
bB. dermatitidis strains: 26199, 18808, Er-3, 14081.
cH. capsulatum strains: G186AR, Nam1, H88, H143.
dC. posadasii strains: C35 D SOWgp, Silveira.
eAspergillus species group 1: A. flavus, A. oryzae, A. terreus.
fAspergillus species group 2: A. nidulans, A. kawachii, A. niger, A. fumigatus 293, A. clavatus.
gF. pedrosoi calnexin sequence is not available (NA); peptide #1 sequences of two related species from the familyHerpotrichiellaceae are shown below
F. pedrosoi.mice, about 1% are tetramer positive, and that proportion more
than doubles after vaccination with calnexin (Figure S5A). After
vaccination with calnexin, 15%–20% of the tetramer-positive
cells in the draining lymph nodes display the chemokine
receptors CCR6 or CXCR3 (Figure S5B), which are linked with,
respectively, Th17 and Th1 cell recruitment (Hirota et al., 2007;
Nanjappa et al., 2012a, 2012b). Nearly 30% of tetramer-positive
cells recruited to the lung were IL-17 producers in calnexin-
vaccinated mice (Figure 4C). Thus, vaccination with calnexin
induces the development of Ag-specific CD4+ T cells that are re-
cruited to the lung after challenge, and this response is linked to
reduced CFU and prolonged survival in association with features
of Th17 and Th1 immunity.
TheRole of TCell Precursor Frequency andExpansion in
Calnexin-Induced Protection
The frequency of naive CD4+ T cell populations affects the size of
the T cell response after immunization with the relevant peptide
(Moon et al., 2007). We tested whether better expansion and
recruitment of calnexin peptide #1-specific CD4+ T cells wouldCellimprove vaccine protection. With calnexin vaccination above,
we observed 100–200 tetramer-positive cells recruited to the
lung after infection, but only about 50 of these cells produced
IL-17, implying that type 17 responses could be further
enhanced.
We first compared different routes of vaccine delivery. The
intravenous (i.v.) route with particles bearing calnexin triggered
better expansion than the subcutaneous (s.c.) route (Figure 5A).
Delivery of soluble peptide #1 with LPS i.v. prompted a
further increase in the number of tetramer-positive cells at
the peak of expansion (Figure 5B), especially at the lowest
dose of 10 mg peptide. Improved expansion of calnexin-spe-
cific T cells did not translate into better protection against
infection compared to the preceding approaches (Figure 5C),
perhaps because only a small fraction of tetramer-positive
cells were recalled to the lungs, and fate-mapping mice
demonstrated that essentially none maintained production
of IL-17. Thus, i.v. delivery promoted better expansion, but dif-
ferentiation or persistence of IL-17 effectors wavered despite
vaccine protection.Host & Microbe 17, 452–465, April 8, 2015 ª2015 Elsevier Inc. 457
Figure 3. Tetramer Enrichment of Endogenous, Fungal-Specific T Cells Ex Vivo
Mice received naive 1807 T cells or not and were infected by doses and routes shown for B. dermatitidis yeast, F. pedrosoi spores, A. fumigatus spores,
H. capsulatum yeast, and P. destructans spores. Seven days post-infection, the skin draining lymph nodes (LN), spleen (SP), or lungs were collected. Calnexin
peptide #1-specific CD4+ T cells were analyzed and quantified after tetramer enrichment as detailed in the Experimental Procedures. Tetramer-positive cells are
shown to the right of the gate in each dot plot. The number represents the geometric mean ± SEM of tetramer-positive cells, with number of mice studied in
parenthesis.Enhanced Vaccine-Induced Expansion of
Calnexin-Specific T Cells
We sought an alternate approach to promote expansion, differ-
entiation, andmaintenance of calnexin-specific T cells to explore458 Cell Host & Microbe 17, 452–465, April 8, 2015 ª2015 Elsevier Intheir role in vaccine protection. We transferred naive 1807 T cells
prior to s.c. vaccination to increase the pool of Ag-experienced
CD4+ T cells that persist. In mice given GP-encapsulated cal-
nexin, we enumerated the number of activated (CD44+) andc.
Figure 4. Vaccine-Induced Resistance Mediated by Calnexin
(A) Mice were vaccinated s.c. thrice, 2 weeks apart, with 108 glucan particles (GP) loaded with 10 mg r-calnexin (Cnx) or mouse serum albumin (MSA) as a control.
Twoweeks after the last boost, mice were challengedwith 23 103B. dermatitidis 26199 yeast or 86 spores ofC. posadasii strain C735. Lung and spleen (latter for
C. posadasii infection) CFUs were assessed 2 weeks post-infection. Numbers indicate the fold difference in lung CFUs versus controls.
(B) Mice were vaccinated s.c. with 25 mg r-calnexin or MSA mixed with 5% or 20% Adjuplex. Two weeks after the last boost, mice were challenged with 23 103
B. dermatitidis, and lung CFUs were measured as in (A). Numbers are the fold difference in lung CFUs versus controls.
(C) IL-17 reporter mice were vaccinated thrice with 25 mg calnexin encapsulated in GMP and mixed with 5% Adjuplex. The histogram shows the mean number of
tetramer-positive cells from the bound and unbound fractions combined. Dot plots show the mean ± SEM number of tetramer-positive and percent of IL-17+
(eYFP+) CD4+ T cells among tetramer-positive and -negative cells from the bound fraction, enumerated by FACS. Dot plots represent an overlay of 10
samples/group.cytokine-producing 1807 T cells upon recall in the lung at day 4
post-infection. The number of CD44+ Ag-specific lung CD4+
T cells increased 41-fold in mice that received 1807 T cells
(11,240 ± 298 1807 cells; Figure 6A) versus those that did notCell(273 ± 19 tetramer-positive cells; Figure 4C). Encouraged by
this finding, we empirically tested different calnexin vaccine for-
mulations to boost the number of Ag-experienced 1807 cells in
the lung upon recall and sway their polarization. Mannan wasHost & Microbe 17, 452–465, April 8, 2015 ª2015 Elsevier Inc. 459
Figure 5. Intravenous Delivery of Calnexin Peptide; Expansion of Endogenous, Tetramer-Specific T Cells; and Resistance to Infection
(A) WT C57BL6 mice were vaccinated s.c. or i.v. with 108 glucan mannan particles (GMP) loaded with 10 mg r-calnexin (Cnx) or MSA as a negative control.
(B) Mice were vaccinated i.v. with 10–250 mg soluble calnexin peptide #1 and 5 mg LPS. Seven days after vaccination in (A) and (B), the skin draining lymph nodes
and spleen were harvested and the number and activation (CD44) of tetramer-positive T cells were assessed. The dot plots represent concatenated samples for
three or four mice (noted in parenthesis) per group. The numbers of tetramer+ CD4+ T cells per concatenated sample is indicated inside the dot plots. Themean ±
SEM of tetramer+ CD4+ T cells per mouse is indicated in the histogram (right). The number over a bar denotes the fold change of tetramer+ T cells versus indicated
control mice.
(C) To assess resistance after i.v. delivery of calnexin peptide, mice were vaccinated thrice with 10 mg soluble peptide #1 plus 5 mg LPS or GP loaded with 10 or
50 mg peptide #1 or MSA as a control. Two weeks after the last boost, mice were challenged with 23 103 B. dermatitidis 26199 yeast. Lung CFUs were assayed
2 weeks post-infection. * and ** denote fold change versus the GMP/MSA or naive control groups, respectively. Dot plots show the mean ± SEM number of
tetramer+, activated (CD44+), and IL-17 differentiated cells (as determined by eYFP fluorescence with IL-17A fate-reporter mice) in the draining lymph nodes and
spleen at the time of challenge, and recalled to the lung 4 days post-infection, concatenated for five mice/group.
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Figure 6. Naive T Cell Precursor Frequency
and Adjuvant Formulation Impact the Pool
Size of Calnexin-Primed T Cells and Resis-
tance to Infection
(A) Mice received 106 naive 1807 cells prior to
vaccination s.c. with 108 glucan particles (GP)
loaded with 10 mg r-calnexin or MSA as a negative
control. Two weeks after the last boost, mice were
challenged with 2 3 103 B. dermatitidis 26199
yeast, and the number of activated (CD44+) and
cytokine-producing 1807 cells was determined by
FACS.
(B) Mice received 106 naive 1807 cells before
vaccination s.c. with 50 mg calnexin or MSA
formulated in GMP or Adjuplex or in GMP and
Adjuplex together. At day 4 post-challenge, the
numbers of CD44+-, IL-17-, and IFN-g-producing
1807 cells were determined by FACS.
(C) Mice received 106 naive 1807 cells and were
vaccinated as in (B). Two weeks after the last
boost, mice were challenged with B. dermatitidis,
and lung CFUs were assayed 2 weeks post-
infection when unvaccinated controls were mori-
bund. Numbers in bold are the fold change versus
MSA-vaccinated controls.added to GP to sway type 17 responses and Adjuplex to drive
type 1 responses. Glucan mannan particles (GMP), Adjuplex,
and the combination of the two together yielded maximal
numbers of IL-17- and IFN-g-producing 1807 T cells in the
lung (Figure 6B), with R 104 recalled 1807 T cells showing an
activated phenotype and R 103 T cells each producing IL-17
or IFN-g. To test whether increased numbers of calnexin-primed
CD4+ T cells translate into improved vaccine resistance, we
determined the lung burden after infection in mice that received
transferred, naive 1807 T cells before vaccination. Calnexin
formulated with GMP and Adjuplex together yielded 3,000-
fold fewer lung CFU than adjuvant-control mice (Figure 6C).
Thus, calnexin is a conserved Ag capable of inducing vaccine
resistance against infection with multiple fungal ascomycetes
if the conditions are optimized for precursor frequency and
expansion and maintenance of T cells that produce IL-17,
IFN-g, or both.
DISCUSSION
We report the discovery of an immunodominant Ag, calnexin,
that is conserved among numerous members of the fungal taxon
Ascomycota. The peptide sequence that induces CD4+ T cell re-
sponses is conserved among the endemic, systemic dimorphic
fungi, as well as clinically important Aspergillus species, Fonse-Cell Host & Microbe 17, 452cea pedrosoi, and even P. destructans,
also referred to as the white nose fungus,
which is sweeping across North America
and devastating bat populations. This
sequence is functionally important for
inducing the expansion of Ag-specific
T cells following exposure to each of
these fungi, and the responses stemmed
progression of ascomycete fungal infec-tions that we studied, including Blastomyces and Coccidioides.
The calnexin sequence diverges in fungi of other taxa, such as
the basidiomycetes, and importantly also in mammals. The cal-
nexin CD4+ T cell epitope is conserved for the inbred mouse
strain studied here. Likewise, humans that have recovered
from certain fungal infections demonstrate recall responses to
calnexin in their CD4+ T cells.
Most of the major fungal antigens reported to date are either
secreted or cell-wall-associated molecules (Rappleye and Gold-
man, 2008). In Blastomyces, the chief Ag BAD1 is both released
and yeast cell wall associated. In Histoplasma, the skin test Ag
histoplasmin is a cell culture filtrate that contains H and M Ags,
which are encoded by a b-glucosidase and catalase, respec-
tively (Deepe and Durose, 1995; Zancope´-Oliveira et al., 1999).
In Cryptococcus spp., mannoproteins in or on the cell wall, or
accumulated in the supernatant, trigger immunity to this fungus
(Levitz and Specht, 2006). In Candida, the principal Ag targets of
vaccines currently under study are Als3, which is a surface adhe-
sin, and Sap2, which is a secreted aspartyl proteinase (Cassone
and Casadevall, 2012). Thus, we were surprised that a protein
such as calnexin, which monitors protein folding and glycosyla-
tion in the ER of cells, would serve as a major trigger of host
cellular immune responses. We found that although calnexin
normally resides in interior cell compartments, anti-calnexin anti-
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and Aspergillus spores and hyphae. While unexpected, this
result is not unprecedented. In Histoplasma, HIS62, a heat-
shock protein (HSP), triggers CD4+ T cells that confer immunity
in response to the fungus (Gomez et al., 1991). HSPs have
been detected on the surface of Histoplasma yeast and mediate
adherence to host integrin receptors (Long et al., 2003). Like-
wise, histone-like proteins have been detected on the surface
of this fungus, and antibodies directed against these proteins
confer immunity (Nosanchuk et al., 2003). The localization of cal-
nexin on the fungal surface could be due to protein shedding
from dead or dying fungi, followed by non-specific adherence
to the surface of viable cells. Alternatively, surface localization
could be due to the trafficking of intracellular molecules through
the cell wall in vesicles, as described in other fungi (Casadevall
et al., 2009). The route notwithstanding, intracellular proteins
including calnexin may unexpectedly appear at the fungal sur-
face and induce immune recognition by the host.
In mapping the T cell epitope of calnexin, we synthesized pep-
tide-MHCII tetramers and exploited this tool to study endoge-
nous CD4+ T cells specific for this sequence on multiple patho-
genic fungi. The pool of naive calnexin-specific cells in a
C57BL/6 mouse is about 30 CD4+ T cells. This pool of T cells ex-
pands in response to exposure to a wide range of fungal asco-
mycetes, including the white nose fungus P. destructans. Our re-
sults supporting the conserved nature of the Ag were confirmed
with TCR transgenic T cells that were adoptively transferred in
parallel into infected mice. While the availability of transgenic
T cells enables themonitoring of Ag-specific immune responses,
transfer of large numbers of T cells has pitfalls and limitations
that may introduce artifacts that distort or misrepresent the
true nature of the immune response to microbes (Moon et al.,
2009). Peptide-MHCII tetramers offer a powerful tool to circum-
vent such limitations. We validated this tool for detecting and
tracking endogenous fungal Ag-specific CD4+ T cell responses
to multiple fungi in a manner that has not been previously avail-
able for the study of immunity to fungi. This tool will offer inves-
tigators studying various fungal pathogens a level of resolution
that has not previously been possible. We show that this tool
can be applied to study fungal diseases that vary from the
endemic, systemic mycoses such as blastomycosis and histo-
plasmosis, to the opportunistic fungal disease Aspergillosis, to
the tropical mycosis chromoblastomycosis, and unexpectedly,
even to the fatal bat disease caused by the white nose fungus.
We used calnexin peptide-MHCII tetramers to track the
behavior of IL-17-producing, Ag-specific CD4+ T cells with the
benefit of fate-mapping mice. We previously demonstrated
that IL-17 production by CD4+ T cells is indispensable in vaccine
immunity against dimorphic fungi that cause North American
systemic mycoses (Nanjappa et al., 2012a; Wu¨thrich et al.,
2011a). We have found that IL-17-producing T cells are main-
tained and persist after vaccination with attenuated yeast in
CD4-sufficient and -deficient mice (Nanjappa et al., 2012a; Wu¨-
thrich et al., 2011a). In contrast, others have reported that IL-17-
producing T cells are short lived and dwindle due to death or
conversion to type 1 cytokine-producing T cells (Hirota et al.,
2011; Pepper et al., 2010). Here, we exploited tetramers to track
fungal Ag-specific, IL-17-producing T cells after vaccination.
Calnexin vaccination induced T cells to differentiate into IL-17
producers, and tetramer-positive cells recalled to the lung after462 Cell Host & Microbe 17, 452–465, April 8, 2015 ª2015 Elsevier Inchallenge included IL-17 producers. These cells dwindled after
i.v. peptide vaccination. In contrast, mice that received trans-
ferred 1807 T cells and s.c. vaccination with GMP and Adjuplex
evinced a large population of IL-17 producers during recall.
Thus, fungal Ag-specific CD4+ T cells that produce IL-17 in
response to vaccination were maintained in the latter setting.
In amurinemodel of cutaneousCandida infection, IL-17-produc-
ing CD4+ T cells did not persist (Hirota et al., 2011). Our findings
are in line with data in humanswhereCandida-responsive, IL-17-
producing T cells persist (Acosta-Rodriguez et al., 2007). Tetra-
mers developed here should allow us to elucidate strategies
to promote the persistence of memory T cells that confer anti-
fungal immunity after vaccine administration.
In view of the conserved nature of calnexin, and its potential
clinical utility for vaccination against pathogenic fungi, we immu-
nized mice with calnexin or its epitopes and tested efficacy
against pulmonary challenge with Blastomyces or Coccidioides.
We encapsulated calnexin in GPs due to the potential advan-
tages of polarizing the immune response toward IL-17-produc-
ing CD4+ T cells (Soto and Ostroff, 2008). Calnexin vaccine pro-
tectedmice against lethal blastomycosis or coccidioidomycosis,
reducing lung CFU by at least 1 log versus control mice. In addi-
tion to calnexin delivery in GPs, we explored adjuvants such as
mannan, LPS, and Adjuplex that may polarize T cells differently;
each gave similar levels of calnexin-induced resistance, and our
results suggest a role for both type 17 and type 1 immunity. Thus,
calnexin could prove to be a valuable component for a ‘‘pan-
fungal’’ vaccine.
The size of the pool of naive precursors specific for calnexin
peptide #1 is an average size (Nelson et al., 2014) of 30 cells.
Because the size of this precursor pool dictates the ultimate
number of Ag-specific T cells in the expanded pool after vaccina-
tion (Moon et al., 2007), we sought to expand this pool to boost
calnexin vaccine efficacy. Delivery of peptide via the i.v. route
lead to an expanded pool of calnexin-specific T cells. In the latter
circumstance, the pool of calnexin-specific T cells increased
to > 1,000 cells in the draining lymph nodes and spleen of cal-
nexin-vaccinated mice, or more than 20-fold higher than the
number of cells in control mice. However, tetramers showed
that Ag-specific effectors were poorly maintained based on
recall, and vaccine efficacy was unchanged.
We investigated cell transfer as an alternate maneuver to in-
crease the size of the precursor pool and boost vaccine efficacy.
Transfer of 1807 T cells led to a 10-fold enhancement of calnexin
peptide-specific T cells recruited to the lungs on challenge;
10,000 of these cells exhibited an activated (CD44+) phenotype
and 10% produced IL-17 or IFN-g (1,000 each). These mice
also had vaccine given s.c. in GMPs in association with Adjuplex
adjuvant so that the independent role of each of these condi-
tions—precursor number versus adjuvant—could not be dis-
cerned. These combined conditions yielded improved vaccine
efficacy, with levels that far exceeded other conditions, resulting
in a 3- to 4-log reduction in lung CFU in a model of lethal exper-
imental fungal infection. We cannot exclude that TCR affinity
played a role in better protection after transfer of transgenic
T cells and vaccination. Nevertheless, T cell transfer has been
used to treat immune-suppressed patients with CMV infections
in the setting of bone marrow or stem cell transplantation (Blyth
et al., 2013; Peggs et al., 2011). Such patients receive donorc.
T cells after expansion of Ag-specific T cells in vitro, followed by
magnetic bead enrichment of activated cytokine-producing
T cells. Another major risk in these patients is pulmonary asper-
gillosis (Singh and Paterson, 2005). Because calnexin is
conserved in Aspergillus and displayed on the fungal surface,
and because the fungus induces expansion of calnexin-specific
CD4+ T cells during infection, transfer of calnexin-specific T cells
that are activated, expanded, and enriched in vitro may offer
immunotherapeutic benefit to patients with invasive fungal
infection (Beck et al., 2006).
EXPERIMENTAL PROCEDURES
Fungi
Strains usedwereWTB. dermatitidisATCC 26199 and strain #55, the isogenic,
attenuated mutant lacking BAD1 (Brandhorst et al., 1999); H. capsulatum
strain G217B; C. posadasii strain C735; C. albicans strain #5314 (Wu¨thrich
et al., 2011b); P. destructans ATCC 20631-21; A. fumigatus Af293; and
F. pedrosoi strain ATCC 46428. Growth conditions are in Supplemental
Experimental Procedures.
Mouse Strains
Inbred C57BL/6, IL-17Atm1.1(icre)Stck/J (stock #16879) and Gt(ROSA)26Sort-
m1(EYFP)Cos reporter mice (stock #6148) were obtained from Jackson Labora-
tory. Breeding IL-17Atm1.1(icre)Stck/J to Gt(ROSA)26Sortm1(EYFP)Cos reporter
mice enabled us to fluorescently label and track IL-17A-expressing cells as
described for fate mapping (Hirota et al., 2011). Blastomyces-specific TCR
Tg 1807 mice were bred to B6.PL (Thy1.1+) mice to obtain Thy1.1+ 1807 cells
(Wu¨thrich et al., 2012).
Generation of Eluate #1
Cell wall membrane (CW/M) Ag was extracted from BAD1 null vaccine yeasts
asdescribed (Wu¨thrich et al., 2000). Briefly, yeastswerebrokenopenwith glass
beads, debris was pelleted, and the aqueous supernatant was harvested. CW/
MAgwas diluted to a protein concentration of 1.5 mg/ml in binding buffer con-
taining 20 mM Tris (pH 7.6), 0.3 M NaCl, 1 mMMnCl2, 1 mMMgCl2, and 1 mM
CaCl2 and centrifuged to remove insoluble complexes. To enrich themannosy-
latedproteins in theCW/MAgpreparation,weusedaConAcolumn (Figure 1A).
See Supplemental Experimental Procedures for details.
Enrichment of the Shared Ag by Gel-free Separation and
Identification by Mass Spectrometry Analysis
Eluate #1wasapplied to agel-free8100 fractionationsystem (ProteinDiscovery)
and separated on a 10% Tris-Acetate cartridge. Fractions were collected that
corresponded to separately elutedMWmarkers. These fractionswere surveyed
for proteincontent byPAGEanalysis andsilver stain. The fractions that activated
1807 T cells (quantified by production of INF-g) were concentrated by filter-
aided sample preparation (FASP) for mass spectrometry analysis (see below).
FASP Method
FASP sample preparation (universal sample preparation method for proteome
analysis) and mass spectrometric analysis were done at the Mass Spectrom-
etry Facility, University of Wisconsin-Madison. Peptides were analyzed by
nano-LC-MS/MS using the Agilent 1100 nanoflow system (Agilent Technolo-
gies) connected to a hybrid linear ion trap-orbitrap mass spectrometer (LTQ-
Orbitrap XL, Thermo Fisher Scientific) equipped with a nanoelectrospray ion
source. See Supplemental Experimental Procedures for detail.
Generation and Purification of r-Calnexin
Calnexin was cloned and expressed in E. coli using standard recombinant
techniques described in Supplemental Experimental Procedures.
GP-Calnexin-MSA/yR, GMP-Calnexin-MSA/yR, GP-MSA/yR, and
GP-MSA/yR Vaccine Formulations
Glucan particles (GPs) and glucanmannan particles (GMPs) were purified from
baker’s yeast using chemical and organic extractions (Soto and Ostroff, 2008;CellYoung et al., 2007). GPs andGMPs containing encapsulated r-calnexin-mouse
serum albumin (MSA; Equitech-Bio) and yeast RNA (yR; Sigma) (G(M)P-cal-
nexin-MSA/yR) or control MSA/yR (G(M)P-MSA/tR) were synthesized (Huang
et al., 2010; Soto and Ostroff, 2008). Vaccine formulations were adjusted to
109 particles/ml in saline for injection (Baxter) and flash-frozen in single-use
aliquots to deliver 10 mg calnexin complexed with 50 mg MSA/108 particles
per 0.1 ml dose. Vaccine Ag identity and encapsulation efficiency (> 95%)
were established by SDS-PAGE. GMP calnexin peptide 1-MSA/yR vaccine
formulations were synthesized as described for calnexin protein.
Generation of MHC Class II Tetramer
To create tetramer, we covalently linked the peptide Ag by a fusion to
the N terminus of the MHCII b chain via a flexible glycine-serine linker
as described (http://www.jenkinslab.umn.edu/Jenkins_Lab_2/assets/pdf/
Jenkins%20tetramer%20production%2004-25-10.pdf and Moon et al.,
2007). Detail on cloning and expression is provided in Supplemental Experi-
mental Procedures.
Enrichment, Staining, and Analysis of Rare Epitope-Specific T Cells
Toenrich epitope-specific Tcells inmice,weusedamagnetic bead-basedpro-
cedure that results in about a 100-fold increase in the frequency of the target
population (Moon et al., 2007, 2009). Enriched cells were stainedwith a cocktail
of fluorochrome-labeled antibodies specific for B220, CD11b, CD11c, F4/80,
CD3, CD8, CD4, and CD44. The entire stained sample was collected on an
LSRII flow cytometer, and live cells were analyzed by FlowJo software (Trees-
tar) following the gating strategy described (Moon et al., 2009). The total num-
ber of tetramer-positive cells from amouse was calculated from the percent of
tetramer-positive events multiplied by the total number of cells in the enriched
fraction as described (Moon et al., 2009) and in the enriched plus unbound
fraction when larger numbers of tetramer positive cells are present.
Stimulation of 1807 T Cells In Vitro
To test the antigenicity of the calnexin protein and peptides, we loaded bone
marrow-derived dendritic cells (BMDCs) with Ag and cultured them with naive
1807 T cells to assess T cell activation and cytokine production. After 3 days of
co-culture, cell supernatants were harvested and analyzed for cytokines by
ELISA and 1807 T cells stained for the activation markers CD44 and CD62L
(Wu¨thrich et al., 2012). Blastomyces CW/M-reactive T cell clone #5, whose
TCR was cloned to generate 1807 transgenic mice (Wu¨thrich et al., 2007),
was also used as a reporter T cell to identify the presence of the Ag. Cell culture
supernatants were generated in 96-well plates in 0.2 ml containing 105
BMDCs, 0.05–10 mg/ml CW/M Ag (Wu¨thrich et al., 2000), 0.05–50 mg/ml
calnexin and Drk1 (as a negative control) (Nemecek et al., 2006), and 0.001–
100 mM calnexin peptides #1–10 (Figure S1). Supernatants were collected
after 72 hr of co-culture. IFN-g and IL-17A were measured by ELISA (R&D
Systems; detection limits were 0.05 ng/ml).
Generation of a Water-Soluble Extract from Vaccine Yeast
Yeast surface proteins were extracted three times with three yeast-pellet vol-
umes of water by agitating the yeast for 1 hr at 4C. Yeasts were separated
from the supernatant by centrifugation and filtration through a 0.2 mm filter.
The water-soluble extract was concentrated by a Centricon column with a
30 kDa cutoff.
Vaccination and Infection
Mice were vaccinated as described (Wu¨thrich et al., 2000) twice, 2 weeks
apart, s.c. with 10–200 mg r-calnexin protein or calnexin peptide. Adjuvants
included CFA, 5%–20% Adjuplex (Advanced BioAdjuvants), and GP without
or with mannan (GMP). Some mice were vaccinated i.v. with 50 mg calnexin
or 10 mg peptide #1 mixed with 5 mg LPS or loaded onto 5 3 107 GMP. Mice
were infected intratracheally (i.t.) with 2 3 103 or 2 3 104 WT yeast of
B. dermatitidis strain 26199, 2 3 105 H. capsulatum G217B, 2 3 105 FKS, or
60 spores of the virulent C. posadasii isolate C735 (Wu¨thrich et al., 2000,
2011a). To assess infiltration of primed CD4 T cells into the lungs, challenged
mice were analyzed at day 4 post-infection. To quantify lung infection, homog-
enized lungs were plated and yeast CFUwere enumerated on BHI agar (Difco),
sheep blood-containing Mycosel plates, or GYE plates containing 50 mg/ml
chloramphenicol.Host & Microbe 17, 452–465, April 8, 2015 ª2015 Elsevier Inc. 463
Adoptive Transfer of 1807 Cells and Experimental Challenge
To assess the T helper cytokine phenotype of calnexin-specific CD4+ T cells
after vaccination with r-calnexin and various adjuvants, we transferred 106
naive 1807 Tg cells into C57BL/6 WT mice before vaccination. On the same
day, recipients were vaccinated, boosted 2 weeks later, and challenged
2 weeks after the boost.
In Vitro Stimulation and Identification of Activated Human T Cells
Peripheral blood mononuclear cells (PBMCs) were isolated from heparinized
whole blood collected over histopaques 1119 and 1077. Studies were
approved by University of Wisconsin-Madison IRB (protocol 2014-1167). Pa-
tients provided informed consent. PBMCswere stimulated with 10 mg/ml r-cal-
nexin, 107/ml heat-killed C. albicans, or crude or purified fungal Ag (10 mg/ml
Blastomyces CW/M, 5 mg/ml Histoplasma CW/M, 100 mg/ml Blastomyces al-
kali-soluble, water-soluble [ASWS] Ag, 10 mg/ml coccidioidin, and 5 mg/mlHis-
toplasma Hsp60) plus 5 U/ml IL-2 and 1 mg/ml a-human CD40 mAb for 14 hr at
37C/5% CO2. After stimulation, cells were bead-enriched by CD154
+ selec-
tion (Miltenyi). Enriched cells were stained with live/dead blue fluorescent
dye (Life Technologies), and a-CD8 PerCP, -CD4 PeCy-7, -CD3 BV785,
-B220 Pacblue, -CD154 PE, and -CD137 APC. B220, CD8, CD3+, and
CD4+ T cells were analyzed for CD137 and CD154 expression using FlowJo.
Statistical Analysis
The number and percent of activated, proliferating, or cytokine-producing
T cells and differences in number of CFU were analyzed using the Wilcoxon
rank test for nonparametric data (Fisher and van Belle, 1993) or the t test
when data were normally distributed. A p value of < 0.05 is considered statis-
tically significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.chom.2015.02.009.
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